The US FDA approval of Pfizer Inc.’s PARP inhibitor Talzenna (talazoparib) for BRCA-mutated breast cancer gives Pfizer another launch in a cancer where it already has extensive experience with its blockbuster Ibrance.
Approved for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, Ibrance (palbociclib) entered the market in 2015 and has been...